Anaemia in patients with inflammatory bowel disease - A nationwide cross-sectional study

Digestion

Volumn 93, Issue 3, 2016, Pages 214-220

  Portela, Francisco ^a,b   Lago, Paula ^b,c   Cotter, José ^b,f   Gonçalves, Raquel ^b,g   Vasconcelos, Helena ^b,h   Ministro, Paula ^b,i   Lopes, Susana ^b,d   Eusébio, Marta ^b,j   Morna, Henrique ^b,k   Cravo, Marilia ^l   Peixe, Paula ^b,m   Cremmers, Isabel ^b,n   Sousa, Helena ^b,o   Deus, João ^b,p   Duarte, Maria ^b,q   Magro, Fernando ^b,e  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b Grupo de Estudos da Doença Inflamatória Intestinal GEDII   (Portugal)

^c HOSPITAL DE SANTO ANTÓNIO   (Portugal)

^d HOSPITAL DE SÃO JOÃO   (Portugal)

^e University of Porto   (Portugal)

^f Centro Hospitalar do Alto Ave ^*  (Portugal)

^g HOSPITAL DE BRAGA   (Portugal)

^h EPE   (Portugal)

ⁱ Centro Hospitalar Tondela Viseu ^*  (Portugal)

^j HOSPITAL DE FARO   (Portugal)

^k Hospital do Funchal   (Portugal)

^l Interventional Pulmonology Section   (Portugal)

^m HOSPITAL EGAS MONIZ   (Portugal)

ⁿ Hospital de Setúbal   (Portugal)

^o Hospital de Portimão   (Portugal)

^p HOSPITAL FERNANDO FONSECA   (Portugal)

^q HOSPITAL DO DIVINO ESPÍRITO SANTO   (Portugal)

more..

Author keywords

Anaemia; Crohn's disease; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

AMINOSALICYLIC ACID DERIVATIVE; CORTICOSTEROID; HEMOGLOBIN; IMMUNOMODULATING AGENT; IRON; MESALAZINE; STEROID; TUMOR NECROSIS FACTOR INHIBITOR; IMMUNOLOGIC FACTOR; NONSTEROID ANTIINFLAMMATORY AGENT; TRACE ELEMENT;

ADULT; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CLINICAL FEATURE; CROHN DISEASE; CROSS-SECTIONAL STUDY; DISEASE ACTIVITY; ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW UP; HUMAN; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PREVALENCE; PRIORITY JOURNAL; REMISSION; ULCERATIVE COLITIS; CLINICAL TRIAL; COMPLICATION; INFLAMMATORY BOWEL DISEASES; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PORTUGAL; SEVERITY OF ILLNESS INDEX;

ADMINISTRATION, ORAL; ADRENAL CORTEX HORMONES; ADULT; ANEMIA; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CROSS-SECTIONAL STUDIES; FEMALE; HEMOGLOBINS; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATORY BOWEL DISEASES; IRON; MALE; MIDDLE AGED; PORTUGAL; PREVALENCE; SEVERITY OF ILLNESS INDEX; TRACE ELEMENTS;

EID: 84962022340     PISSN: 00122823     EISSN: 14219867     Source Type: Journal    
DOI: 10.1159/000443927     Document Type: Article

References (36)

1. Kulnigg S, Gasche C. Systematic review: managing anaemia in Crohn s disease. Aliment Pharmacol Ther 2006; 24: 1507-1523.
2. Gasche C. Complications of inflammatory bowel disease. Hepatogastroenterology 2000; 47: 49-56.
3. Gasche C, Lomer MC, Cavill I, Weiss G. Iron, anaemia, and inflammatory bowel diseases. Gut 2004; 53: 1190-1197.
4. Gasche C. Anemia in IBD: the overlooked villain. Inflamm Bowel Dis 2000; 6: 142-150; discussion 151.
5. Wilson A, Reyes E, Ofman J. Prevalence and outcomes of anemia in inflammatory bowel disease: a systematic review of the literature. Am J Med 2004; 116(suppl 7A): 44S-49S.
6. Gisbert JP, Gomollon F. Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease. Am J Gastroenterol 2008; 103: 1299-1307.
7. Bager P, Befrits R, Wikman O, Lindgren S, Moum B, Hjortswang H, Dahlerup JF. The prevalence of anemia and iron deficiency in IBD outpatients in Scandinavia. Scand J Gastroenterol 2011; 46: 304-309.
8. Rejler M, Tholstrup J, Andersson-Gare B, Spangeus A. Low prevalence of anemia in inflammatory bowel disease: a populationbased study in Sweden. Scand J Gastroenterol 2012; 47: 937-942.
9. Ohira Y, Edgerton VR, Gardner GW, Senewiratne B, Barnard RJ, Simpson DR. Work capacity, heart rate and blood lactate responses to iron treatment. Br J Haematol 1979; 41: 365-372.
10. Wells CW, Lewis S, Barton JR, Corbett S. Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflamm Bowel Dis 2006; 12: 123-130.
11. Cucino C, Sonnenberg A. Cause of death in patients with inflammatory bowel disease. Inflamm Bowel Dis 2001; 7: 250-255.
12. Pizzi LT, Weston CM, Goldfarb NI, Moretti D, Cobb N, Howell JB, Infantolino A, Dimarino AJ, Cohen S. Impact of chronic conditions on quality of life in patients with inflammatory bowel disease. Inflamm Bowel Dis 2006; 12: 47-52.
13. Gasché C, Reinisch W, Lochs H, Parsaei B, Bakos S, Wyatt J, Fueger GF, Gangl A. Anemia in Crohn s disease. Importance of inadequate erythropoietin production and iron deficiency. Dig Dis Sci 1994; 39: 1930-1934.
14. Harvey RF, Bradshaw JM. A simple index of Crohn s-disease activity. Lancet 1980; 1: 514.
15. Walmsley RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut 1998; 43: 29-32.
16. Vermeire S, Schreiber S, Sandborn WJ, Dubois C, Rutgeerts P. Correlation between the Crohn s disease activity and Harvey-Bradshaw indices in assessing Crohn s disease severity. Clin Gastroenterol Hepatol 2010; 8: 357-363.
17. Higgins PD, Schwartz M, Mapili J, Krokos I, Leung J, Zimmermann EM. Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut 2005; 54: 782-788.
18. World Health Organization: Iron Deficiency Anemia Assessment, Prevention and Control. A Guide for Programme Managers. Report No. WHO/NHP/01.3. Geneva, World Health Organization, 2011.
19. Portela F, Magro F, Lago P, Cotter J, Cremers I, de Deus J, Vieira A, Lopes H, Caldeira P, Barros L, Reis J, Carvalho L, Gonçalves R, Campos MJ, Ministro P, Duarte MA, Amil J, Rodrigues S, Azevedo L, Costa-Pereira A. Ulcerative colitis in a Southern European country: a national perspective. Inflamm Bowel Dis 2010; 16: 822-829.
20. Magro F, Portela F, Lago P, Ramos de Deus J, Vieira A, Peixe P, Cremers I, Cotter J, Cravo M, Tavares L, Reis J, Gonçalves R, Lopes H, Caldeira P, Ministro P, Carvalho L, Azevedo L, da Costa-Pereira A; GEDII: Crohn s disease in a southern European country: Montreal classification and clinical activity Inflamm Bowel Dis 2009 15 1343-1350.
21. Bergamaschi G, Di Sabatino A, Albertini R, Ardizzone S, Biancheri P, Bonetti E, Cassinotti A, Cazzola P, Markopoulos K, Massari A, Rosti V, Porro GB, Corazza GR. Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-Tumor necrosis factor-Alpha treatment. Haematologica 2010; 95: 199-205.
22. Høivik ML, Reinisch W, Cvancarova M, Moum B; IBSEN Study Group: Anaemia in inflammatory bowel disease: a populationbased 10-year follow-up Aliment Pharmacol Ther 2014 39 69-76.
23. Filmann N, Rey J, Schneeweiss S, Ardizzone S, Bager P, Bergamaschi G, Koutroubakis I, Lindgren S, Morena Fde L, Moum B, Vavricka SR, Schröder O, Herrmann E, Blumenstein I. Prevalence of anemia in inflammatory bowel diseases in European countries: a systematic review and individual patient data meta-Analysis. Inflamm Bowel Dis 2014; 20: 936-945.
24. de la Morena López F, Gisbert JP: [Prevalence and characteristics of anemia in inflammatory bowel disease] Gastroenterol Hepatol 2009 32 591-599.
25. Goddard AF, McIntyre AS, Scott BB. Guidelines for the management of iron deficiency anaemia. British society of gastroenterology. Gut 2000; 46(suppl 3-4): IV1-IV5.
26. Iron Deficiency Anemia: Assessment, Prevention and Control. Report of a Joint WHO/ UNICEF/UNU Consultation. Geneva, World Health Organization, 2012.
27. Vavricka SR, Schoepfer AM, Safroneeva E, Rogler G, Schwenkglenks M, Achermann R. A shift from oral to intravenous iron supplementation therapy is observed over time in a large Swiss cohort of patients with inflammatory bowel disease. Inflamm Bowel Dis 2013; 19: 840-846.
28. Gisbert JP, Bermejo F, Pajares R, Pérez-Calle JL, Rodrí guez M, Algaba A, Mancenido N, de la Morena F, Carneros JA, McNicholl AG, Gonzá lez-Lama Y, Maté J. Oral and intravenous iron treatment in inflammatory bowel disease: hematological response and quality of life improvement. Inflamm Bowel Dis 2009; 15: 1485-1491.
29. Kulnigg S, Stoinov S, Simanenkov V, Dudar LV, Karnafel W, Garcia LC, Sambuelli AM, D'Haens G, Gasche C. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol 2008; 103: 1182-1192.
30. Khalil A, Goodhand JR, Wahed M, Yeung J, Ali FR, Rampton DS. Efficacy and tolerability of intravenous iron dextran and oral iron in inflammatory bowel disease: a case-matched study in clinical practice. Eur J Gastroenterol Hepatol 2011; 23: 1029-1035.
31. Lindgren S, Wikman O, Befrits R, Blom H, Eriksson A, Grännö C, Ung KA, Hjortswang H, Lindgren A, Unge P. Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: a randomized, controlled, evaluator-blind, multicentre study. Scand J Gastroenterol 2009; 44: 838-845.
32. Carrier J, Aghdassi E, Platt I, Cullen J, Allard JP. Effect of oral iron supplementation on oxidative stress and colonic inflammation in rats with induced colitis. Aliment Pharmacol Ther 2001; 15: 1989-1999.
33. Erichsen K, Ulvik RJ, Nysaeter G, Johansen J, Ostborg J, Berstad A, Berge RK, Hausken T. Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease. Scand J Gastroenterol 2005; 40: 1058-1065.
34. Avni T, Bieber A, Steinmetz T, Leibovici L, Gafter-Gvili A. Treatment of anemia in inflammatory bowel disease - systematic review and meta-Analysis. PLoS One 2013; 8: e75540.
35. Lugg S, Beal F, Nightingale P, Bhala N, Iqbal T. Iron treatment and inflammatory bowel disease: what happens in real practice?. J Crohns Colitis 2014, Epub ahead of print
36. Dignass AU, Gasche C, Bettenworth D, Birgegård G, Danese S, Gisbert JP, Gomollon F, Iqbal T, Katsanos K, Koutroubakis I, Magro F, Savoye G, Stein J, Vavricka S; European Crohn s and Colitis Organisation [ECCO]: European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis 2015; 9: 211-222.